Stereochemistry | ACHIRAL |
Molecular Formula | Al.2O4S.H4N |
Molecular Weight | 237.145 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[NH4+].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
InChI
InChIKey=LCQXXBOSCBRNNT-UHFFFAOYSA-K
InChI=1S/Al.H3N.2H2O4S/c;;2*1-5(2,3)4/h;1H3;2*(H2,1,2,3,4)/q+3;;;/p-3
Molecular Formula | H3N |
Molecular Weight | 17.0305 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HO4S |
Molecular Weight | 97.071 |
Charge | -1 |
Count |
MOL RATIO
2 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Al |
Molecular Weight | 26.9815 |
Charge | 3 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Burow invented an astringent antiseptic solution of aluminium acetate in water to relieve the itching and inflammation of minor skin irritations. At present the oflicial U. S. P. procedure to made Burow's solution involves the reaction of aluminum sulfate, calcium carbonate and acetic acid to form aluminum sub-acetate, also termed basic aluminum acetate.
The solution is available as an over-the-counter drug for topical administration, with brand names including Domeboro. Burow's solution has been shown to be effective against chronic suppurative otitis media and otitis externa. It is active against bacteria resulting in damage to the cell wall.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
The ineffectiveness of aluminum subacetate in rheumatoid arthritis. | 1948 Apr 8 |
|
Cardiovascular manifestations of aluminium phosphide intoxication. | 1989 Sep |
|
Aluminum fluoride inhibition of glucocorticoid receptor inactivation and transformation. | 1990 Apr 10 |
|
Hypermagnesemia following aluminum phosphide poisoning. | 1991 Feb |
|
Manipulation of B cell antigen receptor tyrosine phosphorylation using aluminum fluoride and sodium orthovanadate. | 1995 Nov |
|
The antibacterial activity of acetic acid and Burow's solution as topical otological preparations. | 1998 Oct |
|
Effect of aluminum phosphide on blood glucose level. | 1999 Feb |
|
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study. | 1999 May |
|
Intravascular hemolysis in aluminium phosphide poisoning. | 1999 Sep |
|
Cholinesterase inhibition by aluminium phosphide poisoning in rats and effects of atropine and pralidoxime chloride. | 2001 Jan |
|
Fluoride plus aluminum: useful tools in laboratory investigations, but messengers of false information. | 2002 |
|
Aluminum as a toxicant. | 2002 Aug |
|
Final report on the safety assessment of aluminum silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, sodium magnesium silicate, zirconium silicate, attapulgite, bentonite, Fuller's earth, hectorite, kaolin, lithium magnesium silicate, lithium magnesium sodium silicate, montmorillonite, pyrophyllite, and zeolite. | 2003 |
|
Intracellular mechanisms underlying aluminum-induced apoptosis in rabbit brain. | 2003 Sep 15 |
|
[Pharmaceutical and pharmacological evaluation of Burow's solution (aluminum acetate solution), hospital preparation, and development of its rapid preparation method]. | 2004 Nov |
|
Aluminum: new recognition of an old problem. | 2005 Dec |
|
Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. | 2005 Nov |
|
Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents. | 2006 Nov |
|
The role of aluminum and copper on neuroinflammation and Alzheimer's disease. | 2006 Nov |
|
Ototoxic effect of Burow solution applied to the guinea pig middle ear. | 2007 Aug |
|
Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine. | 2007 Oct |
|
Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. | 2007 Oct |
|
Reversible myocardial injury associated with aluminum phosphide poisoning. | 2007 Sep |
|
Hyperglycemia in acute aluminum phosphide poisoning as a potential prognostic factor. | 2008 Jul |
|
Aluminum phosphide fatalities at mild exertion in asymptomatic children: a clue to understand the variations of the autopsy findings. | 2009 Aug |
|
Effect of acute aluminum phosphide exposure on rats: a biochemical and histological correlation. | 2012 Nov 23 |
|
Gene expression profile of mouse fibroblasts exposed to a biodegradable iron alloy for stents. | 2013 Nov |
|
Molecular basis of carcinogenicity of tungsten alloy particles. | 2015 Mar 15 |
Sample Use Guides
DOMEBORO® SOOTHING SOAK
– dissolve 1 to 3 packets in a pint (16 oz) of cool or warm water
– stir until fully dissolved; do not strain or filter. The resulting mixture contains 0.16% (1 packet), 0.32% (2 packets), or 0.48% (3 packets) aluminum acetate and is ready for use
For use as a soak:
– soak affected area for 15 to 30 minutes as needed, or as directed by a doctor
– repeat 3 times a day or as directed by a doctor
– discard solution after each use.
For use as a compress or wet dressing:
– soak a clean, soft cloth in the solution.
– apply cloth loosely to affected area for 15 to 30 minutes
– repeat as needed or as directed by a doctor
– discard solution after each use
Route of Administration:
Topical
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7784-25-0 | PRIMARY | |||
|
611 | PRIMARY | |||
|
DTXSID7051428 | PRIMARY | |||
|
DPU64XYB1D | PRIMARY | |||
|
m1593 | PRIMARY | Merck Index | ||
|
SUB12870MIG | PRIMARY | |||
|
232-055-3 | PRIMARY | |||
|
24566 | PRIMARY | |||
|
100000077714 | PRIMARY | |||
|
Ammonium alum | PRIMARY | |||
|
146176 | PRIMARY | |||
|
DPU64XYB1D | PRIMARY |